Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK

/in

Consensus group of clinicians have developed a framework of best practice and toolkit for podiatrists treating diabetic foot infections STIMULAN placed in foot wounds following debridement can release antibiotics at therapeutic concentrations  Keele, UK, 3 November 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in […]

Read more

Novo Holdings acquires KabaFusion from Pritzker Private Capital. KabaFusion’s clinician-led management team will remain significant investors in the business alongside Novo Holdings

/in

Novo Holdings, a leading healthcare investment firm, announced today its acquisition of KabaFusion (the “Company”), a leading national provider of home infusion therapies, from Pritzker Private Capital (“PPC”), a leader in family direct investing. Terms of the transaction were not disclosed. Read more here.

Read more

Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia

/in

The grant will enable leading international researchers to complete a clinical trial comparing the two most common treatment methods for preventing leg amputation among people with critical limb ischaemia. Critical limb ischaemia is a serious and debilitating disease that affects about 22 million people globally, and these are often people with diabetes and/or chronic kidney […]

Read more

AMSilk Invited to Participate in VISION 2045 Summit

/in

Leaders from across the world will convene at VISION 2045 Summit which takes place alongside COP27 (the U.N. Climate Change Conference) in November AMSilk will be attending and participating in a panel discussion at the Vision 2045 Summit on ‘Commerce and Industry: What’s Next?’ Munich, Germany, 2 November 2022 – AMSilk GmbH (“AMSilk”), a world leader […]

Read more

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

/in

Funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities Plans to expand platform beyond hemophilia A 02 November 2022, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million in a Series A financing […]

Read more
© Optimum Strategic Communications.